Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Graybug Vision, a clinical-stage biopharmaceutical company focused on retinal and optic nerve diseases, announced that CEO Fred Guerard will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The chat will be available on November 22, 2021, at 10 a.m. ET. Investors can also schedule 1x1 meetings through Piper Sandler. Graybug's lead candidate, GB-102, targets retinal diseases with a six-month or longer dosing regimen, while GB-401 is aimed at glaucoma treatments. For more details, visit Graybug's website.

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.

A link to the fireside chat will also become available at the same time in the Investors and Media section of the company’s website at https://investors.graybug.vision/news-events/events-presentations.

Graybug will be participating in 1x1 meetings with investors during the conference, and meetings can be requested exclusively via Piper Sandler.  

About Graybug

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, the company has offices in Baltimore, Maryland, and Redwood City, California. For more information, please visit www.graybug.vision.

Investor Contact IR@graybug.vision (650) 487-2409

Media Contact media@graybug.vision (404) 384-0067

 

FAQ

When will Graybug Vision's CEO participate in the Piper Sandler conference?

Graybug Vision's CEO Fred Guerard will participate in a pre-recorded fireside chat on November 22, 2021, at 10 a.m. ET.

Where can I watch the Graybug Vision fireside chat?

The fireside chat can be watched on the Piper Sandler conference website and Graybug's Investors and Media section starting at 10 a.m. ET on November 22, 2021.

What is the focus of Graybug Vision's research?

Graybug Vision focuses on developing transformative medicines for diseases of the retina and optic nerve.

What is the lead product candidate of Graybug Vision?

Graybug Vision's lead product candidate is GB-102, which is designed for the treatment of retinal diseases.

How does GB-102 work?

GB-102 is a formulation that targets a six-month or longer dosing regimen to inhibit multiple neovascular pathways for retinal disease treatment.